ATE400253T1 - Verfahren zur gewinnung von mikropartikeln mit a h+, k+ -atp-ase-inhibitor - Google Patents

Verfahren zur gewinnung von mikropartikeln mit a h+, k+ -atp-ase-inhibitor

Info

Publication number
ATE400253T1
ATE400253T1 AT02701872T AT02701872T ATE400253T1 AT E400253 T1 ATE400253 T1 AT E400253T1 AT 02701872 T AT02701872 T AT 02701872T AT 02701872 T AT02701872 T AT 02701872T AT E400253 T1 ATE400253 T1 AT E400253T1
Authority
AT
Austria
Prior art keywords
sup
atp
ase inhibitor
microparticles
obtaining microparticles
Prior art date
Application number
AT02701872T
Other languages
German (de)
English (en)
Inventor
Hakan Glad
Malin Soederbom
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Application granted granted Critical
Publication of ATE400253T1 publication Critical patent/ATE400253T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Disintegrating Or Milling (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • General Preparation And Processing Of Foods (AREA)
AT02701872T 2001-03-09 2002-03-06 Verfahren zur gewinnung von mikropartikeln mit a h+, k+ -atp-ase-inhibitor ATE400253T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0100822A SE0100822D0 (sv) 2001-03-09 2001-03-09 Method II to obtain microparticles

Publications (1)

Publication Number Publication Date
ATE400253T1 true ATE400253T1 (de) 2008-07-15

Family

ID=20283293

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02701872T ATE400253T1 (de) 2001-03-09 2002-03-06 Verfahren zur gewinnung von mikropartikeln mit a h+, k+ -atp-ase-inhibitor

Country Status (21)

Country Link
US (2) US20040101565A1 (enExample)
EP (1) EP1370243B1 (enExample)
JP (1) JP2004522796A (enExample)
KR (1) KR20030081506A (enExample)
CN (1) CN1507343A (enExample)
AT (1) ATE400253T1 (enExample)
AU (1) AU2002235101B8 (enExample)
BR (1) BR0207827A (enExample)
CA (1) CA2440163A1 (enExample)
DE (1) DE60227488D1 (enExample)
DK (1) DK1370243T3 (enExample)
ES (1) ES2307722T3 (enExample)
IL (1) IL157467A0 (enExample)
MX (1) MXPA03007887A (enExample)
NO (1) NO20033966L (enExample)
NZ (1) NZ527997A (enExample)
PT (1) PT1370243E (enExample)
SE (1) SE0100822D0 (enExample)
SI (1) SI1370243T1 (enExample)
WO (1) WO2002072071A1 (enExample)
ZA (1) ZA200306614B (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060159756A1 (en) * 1999-09-10 2006-07-20 Brita Sjoblom Method to obtain microparticles containing an H+,K+-ATP-ASE inhibitor
SE0100823D0 (sv) * 2001-03-09 2001-03-09 Astrazeneca Ab Method I to obtain microparticles
US8067032B2 (en) 2000-12-22 2011-11-29 Baxter International Inc. Method for preparing submicron particles of antineoplastic agents
US6977085B2 (en) 2000-12-22 2005-12-20 Baxter International Inc. Method for preparing submicron suspensions with polymorph control
US6607784B2 (en) 2000-12-22 2003-08-19 Baxter International Inc. Microprecipitation method for preparing submicron suspensions
US9700866B2 (en) 2000-12-22 2017-07-11 Baxter International Inc. Surfactant systems for delivery of organic compounds
US6884436B2 (en) 2000-12-22 2005-04-26 Baxter International Inc. Method for preparing submicron particle suspensions
US6951656B2 (en) 2000-12-22 2005-10-04 Baxter International Inc. Microprecipitation method for preparing submicron suspensions
US7193084B2 (en) 2000-12-22 2007-03-20 Baxter International Inc. Polymorphic form of itraconazole
SE0100824D0 (sv) * 2001-03-09 2001-03-09 Astrazeneca Ab Method III to obtain microparticles
SE0100822D0 (sv) * 2001-03-09 2001-03-09 Astrazeneca Ab Method II to obtain microparticles
CN1558755A (zh) 2001-09-26 2004-12-29 ���ع��ʹ�˾ 通过分散和除去溶剂或液相制备亚微米大小的纳米颗粒
US20060003012A9 (en) 2001-09-26 2006-01-05 Sean Brynjelsen Preparation of submicron solid particle suspensions by sonication of multiphase systems
US7112340B2 (en) 2001-10-19 2006-09-26 Baxter International Inc. Compositions of and method for preparing stable particles in a frozen aqueous matrix
CA2518780C (en) 2003-03-12 2014-05-13 Takeda Pharmaceutical Company Limited Drug composition having active ingredient adhered at high concentration to spherical core
DE10325989A1 (de) * 2003-06-07 2005-01-05 Glatt Gmbh Verfahren zur Herstellung von und daraus resultierende Mikropellets sowie deren Verwendung
US20050181052A1 (en) * 2004-02-17 2005-08-18 Patel Satishkumar A. Lansoprazole microtablets
WO2007095376A2 (en) * 2006-02-15 2007-08-23 Kennametal Inc. Method and apparatus for coating particulates utilizing physical vapor deposition
CH698658B1 (de) * 2006-04-24 2009-09-30 Mepha Ag Orale pharmazeutische Formulierung mit schneller Freisetzung für Pyridylmethylsulfinyl-Benzimidazole.
US20090087569A1 (en) * 2007-09-27 2009-04-02 Fenchem Enterprises Ltd. Methods for Preparing Highly Stable Hyaluronic Acid
IT1401284B1 (it) * 2010-08-06 2013-07-18 Valpharma S P A Nuove formulazioni farmaceutiche idonee per la somministrazione orale di esomeprazolo magnesio diidrato, in forma di compresse mups (multi unit pellets system).
WO2017145146A1 (en) 2016-02-25 2017-08-31 Dexcel Pharma Technologies Ltd. Compositions comprising proton pump inhibitors
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
WO2021153525A1 (ja) * 2020-01-27 2021-08-05 東和薬品株式会社 エソメプラゾール経口製剤およびその製造方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3565475D1 (en) * 1984-04-07 1988-11-17 Bayer Ag Process and apparatus for the production of granules
IL75400A (en) * 1984-06-16 1988-10-31 Byk Gulden Lomberg Chem Fab Dialkoxypyridine methyl(sulfinyl or sulfonyl)benzimidazoles,processes for the preparation thereof and pharmaceutical compositions containing the same
GB2189698A (en) * 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
DE3909455A1 (de) * 1989-03-22 1990-09-27 Hoechst Ag Verfahren zur herstellung von wasserdispergierbaren granulaten
WO1996001623A1 (en) * 1994-07-08 1996-01-25 Astra Aktiebolag Multiple unit tableted dosage form i
FR2725623A1 (fr) * 1994-10-18 1996-04-19 Flamel Tech Sa Microcapsules medicamenteuses et/ou nutritionnelles pour administration per os
DE19613395A1 (de) * 1996-04-03 1997-10-09 Basf Ag Granulate hygroskopischer, wasserlöslicher Produkte
DE19733094A1 (de) * 1997-07-31 1999-02-04 Merck Patent Gmbh Formulierung auf der Basis von Ascorbinsäure mit verbesserter Farbstabilität
WO1999018935A1 (de) * 1997-10-15 1999-04-22 Merck Patent Gmbh Herstellung eines direkt verpressbaren tablettierhilfsstoffes
US6174548B1 (en) * 1998-08-28 2001-01-16 Andrx Pharmaceuticals, Inc. Omeprazole formulation
HUP0100065A2 (hu) * 1997-12-08 2001-08-28 Byk Gulden Lomberg Chemische Fabrik Gmbh. Savérzékeny vegyületet tartalmazó új kúp gyógyszerforma
SE9903236D0 (sv) * 1999-09-10 1999-09-10 Astra Ab Method to obtain microparticles
SE0100823D0 (sv) * 2001-03-09 2001-03-09 Astrazeneca Ab Method I to obtain microparticles
US20060159756A1 (en) * 1999-09-10 2006-07-20 Brita Sjoblom Method to obtain microparticles containing an H+,K+-ATP-ASE inhibitor
SE0100822D0 (sv) * 2001-03-09 2001-03-09 Astrazeneca Ab Method II to obtain microparticles
SE0100824D0 (sv) * 2001-03-09 2001-03-09 Astrazeneca Ab Method III to obtain microparticles

Also Published As

Publication number Publication date
IL157467A0 (en) 2004-03-28
WO2002072071A1 (en) 2002-09-19
NO20033966L (no) 2003-11-03
JP2004522796A (ja) 2004-07-29
CA2440163A1 (en) 2002-09-19
AU2002235101B8 (en) 2006-08-31
PT1370243E (pt) 2008-09-16
US20080175917A1 (en) 2008-07-24
ZA200306614B (en) 2004-11-25
AU2002235101B2 (en) 2006-07-13
US20040101565A1 (en) 2004-05-27
ES2307722T3 (es) 2008-12-01
NZ527997A (en) 2005-02-25
SI1370243T1 (sl) 2008-12-31
EP1370243A1 (en) 2003-12-17
EP1370243B1 (en) 2008-07-09
MXPA03007887A (es) 2003-12-04
HK1059896A1 (en) 2004-07-23
CN1507343A (zh) 2004-06-23
DK1370243T3 (da) 2008-10-13
KR20030081506A (ko) 2003-10-17
NO20033966D0 (no) 2003-09-08
SE0100822D0 (sv) 2001-03-09
DE60227488D1 (de) 2008-08-21
BR0207827A (pt) 2004-03-02

Similar Documents

Publication Publication Date Title
ATE400253T1 (de) Verfahren zur gewinnung von mikropartikeln mit a h+, k+ -atp-ase-inhibitor
CY1107488T1 (el) Σταθερα ξηραμενα δια ψεκασμου πρωτεϊνικα σκευασματα
CY1119742T1 (el) Βιολογικα συστηματα μεταφορας πολλαπλου-συστατικου
DE60227709D1 (de) Die verwendung von c-kithemmern zur behandlung von autoimmunerkrankungen
ATE363290T1 (de) Cd40 antagonist zur behandlung von psoriasis
DE69933763D1 (de) Biologisch abbaubares alginatgel mit verzögerter freisetzung
TR199802385T2 (xx) TNF inhibit�rleri ve FDE-IV inhibit�rleri olarak kinolin karboksamidler.
CY1111279T1 (el) Αμμος ζωων
AP2003002742A0 (en) Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids
ATE311363T1 (de) Sulfohydroxamsäure and sulfohydroxamate und ihre verwendung als mek-inhibitoren
DK0986382T3 (da) RAF-kinasehæmmere
BR0116969A (pt) método e sistema de gerenciamento de resìduo
TR199801579T2 (xx) Polimerlere dayanan b�cek �ld�r�c� bile�imler.
BRPI0408466B8 (pt) composição farmacêutica e uso de inibidor de proteína de transferência de colesteril éster e crospovidona
BRPI0514411B8 (pt) formulação, e, método de produzir uma formulação
BR0209950A (pt) Composição estabilizadora finamente distribuìda para polìmeros contendo halogênio
AR038332A1 (es) Compuestos que son metabolitos del acido (3-{[(4-terc-butilbencil)-(piridin-3-sulfonil)amino]metil}fenoxi) acetico, composiciones farmaceuticas que los contienen, y procedimiento de determinacion
MXPA04005129A (es) Uso de diamina de acido piridin-2,4-dicarboxilico y de diaminas de acido pirimidin-4,6-dicarboxilico para la inhibicion selectiva de la colagenasa.
DE60017538D1 (de) Als biodegradationsbeschleuniger verwendbare sprühbare ernährungsmicroemulsion
ATE298747T1 (de) Verfahren zur herstellung von 5- hydroxybenzo(b)thiophen-3-carbonsäure
ATE440895T1 (de) Expandierbare polyolefinpartikel
MY135375A (en) Pyrimidine-4,6-dicarboxylic acid diamides for selectively inhibiting collagenases
ATE237346T1 (de) Gebrauch von galanin um nervenschäden zu reparieren
PL373247A1 (en) Method for treating tumors by the administration of tegafur, uracil, folinic acid, and cyclophosphamide
ATE385175T1 (de) Hemmung von tyrophagus putrescentiae in tierfuttermitteln

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1370243

Country of ref document: EP

REN Ceased due to non-payment of the annual fee